OR WAIT null SECS
July 07, 2026
Article
FDA grants Priority Review to Agios’ mitapivat sNDA for sickle cell disease, with a PDUFA date set for November 1, 2026.
July 02, 2026
Exagamglogene autotemcel (Casgevy) is now the first CRISPR-based gene-editing therapy to reach this age group in either condition.
May 16, 2026
Stay updated with the latest healthcare breakthroughs, including FDA submissions and new cardiology guidelines.
May 11, 2026
Catch up on the hematology news and data you missed from April 2026.
April 29, 2026
Video
Inusa discusses how clinicians can close gaps in sickle cell disease care and global disparities.
April 28, 2026
Study investigator Inusa explains the gap in sickle cell disease findings from SWAP, a multinational survey.
April 27, 2026
Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.
April 21, 2026
Hanna explains the real-world barriers to implementing gene editing therapies in sickle cell disease.
April 20, 2026
Etavopivat reduced VOC events by 27% and improved hemoglobin response in the phase 3 HIBISCUS trial in sickle cell disease.
April 17, 2026
Hanna describes the "freedom" patients with sickle cell disease reported after being treated with reni-cel, a one-time edited gene therapy.